PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

BOSTON, Sept. 27, 2023 -- PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe...

Related Keywords

South Carolina ,United States ,Charleston ,Boston ,Massachusetts ,Ashling Holland ,Laurence Watts ,Jennifer Shoskes ,Sarah Sutton ,Nasdaq ,Head Of Clinical Development ,Pepgen Inc ,World Muscle Society ,Gilmartin Group ,Trial Designs To Support The Development ,Preclinical Development ,Clinical Development ,Annual Congress ,High Levels ,Exon Skipping ,Duchenne Muscular Dystrophy ,Michelle Mellion ,Senior Vice President ,Dose Nonclinical Data ,Trial Designs ,Duchenne Muscular Dystrophy Amenable ,Duchenne Muscular Dystrophy Mediate High Levels ,Data Demonstrate Mechanistic ,Meaningful Activity ,Potential Treatment ,Myotonic Dystrophy Type ,Assess Safety ,Associate Director ,Enhanced Delivery Oligonucleotide ,Private Securities Litigation Reform Act ,Markets ,